Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
ApexOnco Front Page
Recent articles
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
ELVN-001 is made to look more like Terns’ TERN-701.
Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
Four months after yielding first-in-human data INCA33890 enters phase 3.
But Tevimbra’s role looks shaky as adverse events loom.
JP Morgan approaches.
